NBIX

Neurocrine Biosciences Inc

NBIX, USA

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

https://www.neurocrine.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NBIX
stock
NBIX

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares MarketBeat

Read more →
NBIX
stock
NBIX

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$174.9911

Analyst Picks

Strong Buy

15

Buy

7

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Low

35.92

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

5.15

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

6.97 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.91 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

26.96 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.42

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 90.30% of the total shares of Neurocrine Biosciences Inc

1.

BlackRock Inc

(13.0617%)

since

2025/06/30

2.

Vanguard Group Inc

(9.888%)

since

2025/06/30

3.

Dodge & Cox

(5.6128%)

since

2025/06/30

4.

State Street Corp

(4.5051%)

since

2025/06/30

5.

JPMorgan Chase & Co

(4.2969%)

since

2025/06/30

6.

Dodge & Cox Stock I

(3.9967%)

since

2025/06/30

7.

iShares Core S&P Mid-Cap ETF

(3.2473%)

since

2025/08/31

8.

Vanguard Total Stock Mkt Idx Inv

(3.141%)

since

2025/07/31

9.

T. Rowe Price Associates, Inc.

(3.1119%)

since

2025/06/30

10.

Vanguard Small Cap Index

(2.4227%)

since

2025/07/31

11.

Renaissance Technologies Corp

(2.3859%)

since

2025/06/30

12.

Citadel Advisors Llc

(2.066%)

since

2025/06/30

13.

Wellington Management Company LLP

(2.0456%)

since

2025/06/30

14.

Geode Capital Management, LLC

(1.9754%)

since

2025/06/30

15.

Bellevue Group AG

(1.835%)

since

2025/06/30

16.

BB Biotech AG Ord

(1.835%)

since

2024/12/31

17.

Morgan Stanley - Brokerage Accounts

(1.8348%)

since

2025/06/30

18.

AQR Capital Management LLC

(1.5225%)

since

2025/06/30

19.

UBS Asset Mgmt Americas Inc

(1.3991%)

since

2025/06/30

20.

Vanguard Small Cap Growth Index Inv

(1.3641%)

since

2025/07/31

21.

Millennium Management LLC

(1.2041%)

since

2025/06/30

22.

Deerfield Management Co

(1.1774%)

since

2025/06/30

23.

BRAIDWELL LP

(1.17%)

since

2025/06/30

24.

Vanguard Windsor Investor Shares

(1.1431%)

since

2025/06/30

25.

JPM US Mid Cap Growth-Composite

(1.1249%)

since

2025/06/30

26.

JPMorgan Mid Cap Growth I

(1.1214%)

since

2025/07/31

27.

T. Rowe Price US Mid-Cap Value Equity

(1.0738%)

since

2025/06/30

28.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0728%)

since

2025/07/31

29.

T. Rowe Price Mid-Cap Value

(1.0722%)

since

2025/07/31

30.

RTW INVESTMENTS, LLC

(1.0708%)

since

2025/06/30

31.

BNP Paribas Investment Partners SA

(1.0408%)

since

2025/06/30

32.

NORGES BANK

(0.9809%)

since

2025/06/30

33.

SPDR® S&P Biotech ETF

(0.9525%)

since

2025/08/31

34.

JPMorgan Growth Advantage A

(0.9337%)

since

2025/07/31

35.

SPDR® S&P MIDCAP 400 ETF Trust

(0.7643%)

since

2025/07/31

36.

T. Rowe Price U.S. Mid-Cap Val Eq Tr-D

(0.5771%)

since

2025/06/30

37.

iShares Biotechnology ETF

(0.5741%)

since

2025/08/31

38.

iShares S&P Mid-Cap 400 Growth ETF

(0.5682%)

since

2025/08/31

39.

T. Rowe Price Health Sciences

(0.5653%)

since

2025/07/31

40.

iShares MSCI USA Min Vol Factor ETF

(0.5604%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.81

Latest Release

Date

2025-09-30

EPS Actual

2.17

EPS Estimate

2.09

EPS Difference

0.08

Surprise Percent

3.8278%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9)
GARP
Strong GARP(7.5)
Growth
Moderate Growth(6)
Momentum
Strong Momentum(6.5)
Net Net
Possible Net-Net(4)
Quality
High Quality(8.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.